Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular

Anna Bochicchio1,2,3, Sandra Jordaan4, Valeria Losasso5

  • 1German Research School for Simulation Sciences, Forschungszentrum Jülich, Jülich 52425, Germany. a.bochicchio@fz-juelich.de.

Biomedicines
|May 25, 2017
PubMed

Insights

Targeted human cytolytic fusion proteins (hCFPs) show promise for cancer treatment but are hindered by natural inhibitors. In silico methods like molecular dynamics (MD) and enhanced sampling methods (ESM) are advancing hCFP design by predicting inhibitor binding and guiding mutations for improved efficacy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Computational Biology

Background:

  • Targeted human cytolytic fusion proteins (hCFPs) are engineered immunotoxins for selective disease treatment, particularly cancer.
  • hCFPs utilize a targeting ligand and a human apoptosis-inducing enzyme to eliminate diseased cells after internalization.
  • Cancer cells can evade hCFPs by upregulating native inhibitors (Serpin P9, RNH1) that neutralize effector enzymes like Granzyme B and Angiogenin.

Purpose of the Study:

  • To explore the use of in silico methods, specifically molecular dynamics (MD) and enhanced sampling methods (ESM), for designing more potent hCFPs.
  • To investigate how to overcome inhibitor-mediated resistance in hCFPs by designing enzyme variants with reduced inhibitor affinity.
  • To leverage computational approaches for identifying specific mutations that enhance hCFP efficacy.

Main Methods:

  • Molecular dynamics (MD) simulations to predict enzyme-inhibitor binding stability.
  • Enhanced sampling methods (ESM) to analyze conformational changes and binding interactions.
  • In silico design of hCFP mutants with potentially altered inhibitor binding affinities.

Main Results:

  • MD and ESM provide high-resolution insights into enzyme-inhibitor interactions.
  • These computational tools can identify specific interaction domains and mutation sites to modify binding.
  • The approach facilitates the rational design of hCFP variants with improved potency against cancer cells.

Conclusions:

  • In silico methods like MD and ESM are powerful tools for advancing hCFP development.
  • These methods enable the design of hCFPs that overcome inhibitor resistance, leading to more effective cancer therapies.
  • Further integration of computational and experimental approaches will accelerate the creation of next-generation hCFPs.